英文名稱 | AZD-9291 (Osimertinib; Mereletinib) |
---|---|
中文名稱 | 奧希替尼/邁瑞替尼 |
CAS號(hào) | 1421373-65-0 |
分子式 | C28H33N7O2 |
分子量 | 499.62 |
外觀 | Off-white powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專享價(jià) | 數(shù)量 |
---|---|---|---|---|
250 mg | In-stock | ¥300.00 | 登錄后可見(jiàn) | |
1 g | In-stock | ¥850.00 | 登錄后可見(jiàn) |
英文名稱 | AZD-9291 (Osimertinib; Mereletinib) |
---|---|
中文名稱 | 奧希替尼/邁瑞替尼 |
CAS號(hào) | 1421373-65-0 |
分子式 | C28H33N7O2 |
分子量 | 499.62 |
外觀 | Off-white powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Osimertinib, also known as AZD-9291 and Mereletinib, is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines. Osimertinib was approved in Nov. 2015 by FDA.